Lakefront Biotherapeutics NV
LKFT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001421876
No open-market purchases or sales by Lakefront Biotherapeutics NV insiders were filed in the last 90 days; 76 institutions reported holding it in 13F filings for Q2 2026, worth $960.3M in total; Greenlight Capital is the only superinvestor holding it.
Other share classesGLPGF
Superinvestors holding LKFT, Q2 2026
1 superinvestor reports holding Lakefront Biotherapeutics NV on Form 13F, worth $14.5M in total. Weight is Lakefront Biotherapeutics NV's share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Greenlight CapitalDavid Einhorn | 0.4% | 482,746 | $14.5M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of LKFT each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2025
1 superinvestor holding at quarter end
- Added
- Greenlight Capital (+0.7%)
Q3 2024
1 superinvestor holding at quarter end
- Added
- Greenlight Capital (+104.1%)
Q2 2024
1 superinvestor holding at quarter end
- Added
- Greenlight Capital (+46.9%)
Q1 2024
1 superinvestor holding at quarter end
- Reduced
- Greenlight Capital (−1.7%)
Q4 2023
1 superinvestor holding at quarter end
- Added
- Greenlight Capital (+4.0%)
Q3 2023
1 superinvestor holding at quarter end
- Added
- Greenlight Capital (+4.1%)
Q2 2023
1 superinvestor holding at quarter end
- Reduced
- Greenlight Capital (−0.8%)
Q1 2023
1 superinvestor holding at quarter end
- Reduced
- Greenlight Capital (−2.6%)
Q4 2022
1 superinvestor holding at quarter end
- Added
- Greenlight Capital (+6.1%)
Q2 2022
1 superinvestor holding at quarter end
- Reduced
- Greenlight Capital (−8.6%)
Q1 2022
1 superinvestor holding at quarter end
- Reduced
- Greenlight Capital (−13.4%)
Q4 2021
1 superinvestor holding at quarter end